The attrition rate in drug development has remained stubbornly resistant to decades of technological advancement. Roughly 90 percent of drug candidates that enter clinical trials fail to reach approval, and a substantial share of that failure traces back to a basic mismatch: the preclinical models used to predict efficacy and safety do not adequately represent human biology. Two-dimensional cell cultures are scalable but biologically reductive. Animal models add organismal context but frequently fail to recapitulate human tumor architecture, clonal heterogeneity, and patient-specific drug response. The result is a persistent translational gap between what preclinical data suggests and what actually happens in patients.
Three-dimensional culture systems — organoids and multicellular spheroids — have emerged as the most direct response to that mismatch. Rather than asking cells to behave like tissue while growing in a flat monolayer, these models allow cells to self-organize into structures that preserve key architectural and functional features of the organs or tumors they are derived from. The result is a preclinical system that more closely mirrors the spatial organization, cell-cell interactions, and microenvironmental complexity of human biology.
What 3D models capture that flat cultures cannot
The biological case for 3D culture systems rests on a straightforward observation: Cells behave differently depending on their physical and chemical context. A 2026 study in Nature Reviews Drug Discovery described human organoids as providing physiologically relevant three-dimensional models for studying disease mechanisms, drug efficacy, and toxicity — citing their capacity to capture the complexity and heterogeneity of human tissues in ways that conventional two-dimensional cell lines cannot.
That heterogeneity has direct consequences for drug screening outcomes. Spheroid models have been shown to exhibit higher chemical resistance when responding to drug treatment compared with 2D cultures, more accurately simulating the tumor microenvironment and providing greater predictive value for drug effectiveness. The same resistance that makes spheroid-based assays more demanding to interpret is precisely what makes them more clinically informative: a compound that clears cancer cells in a 2D monolayer but fails against a 3D spheroid is providing information about drug penetration, microenvironmental interaction, and cellular adaptation that a flat culture system structurally cannot reveal.
Patient-derived organoids extend this advantage further. Generated from adult stem cells and expanded as three-dimensional structures often described as miniature organ systems, patient-derived organoids preserve key features of the originating tissue specimen — including histopathology, genomic landscape, and functional drug response phenotypes. That preservation allows researchers to assess individual drug responses using material derived directly from the patient population a therapy is intended to treat, rather than relying solely on established cell lines or animal models with uncertain translational relevance.
The reproducibility challenge
The promise of 3D models has always come paired with a practical complication: these systems are harder to generate, control, and measure consistently than the 2D cultures they are meant to improve upon. Variability in spheroid size, organoid morphology, and growth kinetics can introduce technical noise that obscures the biological signal these models are meant to capture.
That variability is not a minor inconvenience. Differences in spheroid uniformity affect how signaling molecules and growth factors penetrate the tissue, producing cells that mature at different rates depending on structural variation between replicates — undermining the controlled conditions that reliable screening assays require. Addressing this has driven significant innovation in culture techniques, plate formats, and imaging approaches designed to generate more uniform 3D structures and to monitor their development consistently over time without disrupting the culture environment.
Imaging itself presents a distinct technical challenge in 3D systems. Optical microscopy approaches that work well for flat, single-layer cultures often struggle with the narrow field of view and shallow depth of penetration required to resolve structures that extend through three dimensions.
Toward regulatory integration
What distinguishes the current moment in 3D culture research from earlier phases of organoid and spheroid development is the degree to which regulatory frameworks are beginning to formally recognize these models as legitimate components of the preclinical evidence base. In April 2025, the US Food and Drug Administration (FDA) announced a plan to phase out certain animal testing requirements in favor of New Approach Methodologies (NAMs) — a category that explicitly includes organoid-based efficacy and toxicity testing alongside computational and AI-driven approaches.
A March 2026 review in Drug Discovery Today examined this shift directly, noting that organoids enable predictive assessments of drug efficacy, toxicity, and pharmacokinetics that offer superior physiological relevance over traditional 2D and animal models — while emphasizing that harmonized regulatory frameworks are essential to ensure scientific rigor and facilitate broader adoption of organoid technologies in drug development. The integration of artificial intelligence-driven modeling with organoid-generated data was identified as a particularly active area of expansion, especially in oncology applications where patient-derived organoid responses can inform both target validation and biomarker development.
This regulatory dimension matters because it changes the strategic calculus for drug developers. A 3D model that exists purely as a research tool occupies a different position in a development program than one that regulators recognize as contributing meaningfully to a safety or efficacy submission. As the qualification pathways for organoid-based evidence mature, the incentive to invest in generating robust, reproducible, well-characterized 3D model data earlier in the discovery process increases correspondingly.
What reliable 3D research now requires
The trajectory of 3D culture research points toward systems that are not just biologically richer than 2D alternatives but operationally comparable to them — generating data at the throughput, consistency, and analytical depth that drug discovery programs require to make confident decisions.
A 2025 study examining multi-scale imaging approaches for 3D cell cultures, published in Nature Methods, described the challenge of understanding the complex cellular organization within organoids as requiring integration of imaging modalities across spatial and temporal scales — from millimeter-scale live observation of organoid growth to nanometer-scale structural analysis of subcellular architecture. That kind of multi-scale characterization, applied systematically and reproducibly, is what separates organoid and spheroid systems used as occasional research tools from those capable of supporting routine, decision-grade preclinical screening.
For drug discovery teams, the practical implications center on three areas: investing in culture and imaging protocols that minimize structural variability between replicates, since that variability directly determines whether 3D assay readouts reflect biology or noise; building analytical pipelines capable of extracting quantitative, comparable measurements from inherently complex three-dimensional structures rather than treating them as a richer version of a 2D endpoint assay; and tracking the evolving regulatory landscape for NAMs closely, since the qualification status of 3D model data will increasingly determine how that data can be used in development programs.
The translational gap between preclinical promise and clinical reality has defined drug development for decades. Three-dimensional culture systems do not eliminate that gap, but they represent one of the more biologically grounded efforts to narrow it — by asking cells to behave, as closely as a dish allows, like the tissue they are meant to represent.
